Clinical Trial Update: Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety and efficacy of low-dose pentavalent antimony for cutaneous leishmaniasis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Pentavalent antimony (sodium stibogluconate) (sodium stibogluconate)

Snippet

Sponsor: University of Brasilia | Conditions: Cutaneous Leishmaniasis | Phase 4 | Status: COMPLETED